Cellectis (PA:ALCLS) — Stock Price
Cellectis (PA:ALCLS) is currently trading at €2.48 EUR, up 2.74% today. Over the past 52 weeks, shares have ranged between €2.21 and €4.57. This page tracks Cellectis's live share price on the PA exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see ALCLS market cap.
Cellectis (ALCLS) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Cellectis's daily closing share price and trading volume on the PA exchange over the past year, giving a clear view of recent price momentum and liquidity.
Cellectis Income Statement — Revenue, Profit & Earnings by Year
Cellectis's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €75.92 Million | €41.51 Million | €755.00K | €19.17 Million | €73.95 Million |
| Cost of Revenue | €20.88 Million | €9.18 Million | €737.00K | €1.77 Million | €36.27 Million |
| Gross Profit | €55.04 Million | €41.51 Million | €18.00K | €17.40 Million | €37.67 Million |
| Research & Development | €97.33 Million | €90.54 Million | €87.65 Million | €97.50 Million | €86.95 Million |
| SG&A | €8.60 Million | €17.60 Million | €16.81 Million | €17.49 Million | €37.87 Million |
| Total Operating Expenses | €97.05 Million | €101.06 Million | €97.32 Million | €107.06 Million | €123.11 Million |
| Operating Income | €-42.00 Million | €-59.55 Million | €-97.30 Million | €-89.67 Million | €-85.44 Million |
| EBITDA | €-21.12 Million | €-9.46 Million | €-92.64 Million | €-71.23 Million | €-68.87 Million |
| EBIT | €-42.00 Million | €-29.31 Million | €-111.16 Million | €-89.67 Million | €-85.44 Million |
| Interest Expense | €8.44 Million | €7.45 Million | €5.31 Million | €3.79 Million | €5.34 Million |
| Income Before Tax | €-77.70 Million | €-36.76 Million | €-116.46 Million | €-98.60 Million | €-97.48 Million |
| Income Tax Expense | €-7.36 Million | — | €371.00K | €87.00K | €-11.20 Million |
| Net Income | €-70.35 Million | €-36.76 Million | €-101.06 Million | €-98.69 Million | €-86.28 Million |
Cellectis Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Cellectis's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €324.76 Million | €383.54 Million | €334.27 Million | €261.22 Million | €382.08 Million |
| Total Current Assets | €236.27 Million | €287.07 Million | €233.01 Million | €143.81 Million | €225.43 Million |
| Cash & Equivalents | €15.62 Million | €110.34 Million | €55.00 Million | €11.20 Million | €47.91 Million |
| Short-term Investments | €145.10 Million | €117.06 Million | €67.11 Million | €7.91 Million | €499.00K |
| Net Receivables | €22.20 Million | €23.04 Million | €23.13 Million | €772.00K | €20.36 Million |
| Inventory | — | — | €89.67 Million | €21.77 Million | €0.00 |
| Property, Plant & Equipment | €62.45 Million | €75.86 Million | €92.74 Million | €107.90 Million | €148.27 Million |
| Goodwill | — | — | €-1.00K | — | €1.00K |
| Total Liabilities | €248.85 Million | €252.51 Million | €249.57 Million | €135.28 Million | €145.60 Million |
| Total Current Liabilities | €145.77 Million | €166.27 Million | €155.14 Million | €62.99 Million | €49.35 Million |
| Long-term Debt | €51.22 Million | €43.99 Million | €28.44 Million | €20.53 Million | €20.03 Million |
| Net Debt | €56.32 Million | €-51.79 Million | €-51.65 Million | €-14.85 Million | €-83.90 Million |
| Total Stockholder Equity | €75.91 Million | €131.03 Million | €84.69 Million | €117.97 Million | €221.29 Million |
| Retained Earnings | €-334.17 Million | €-329.61 Million | €-405.77 Million | €-439.50 Million | €-698.33 Million |
Cellectis Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Cellectis generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €-41.64 Million | €22.99 Million | €-24.75 Million | €-87.44 Million | €-104.56 Million |
| Capital Expenditures | €2.46 Million | €3.84 Million | €1.07 Million | €2.44 Million | €19.74 Million |
| Free Cash Flow | €-44.10 Million | €19.15 Million | €-25.82 Million | €-89.89 Million | €-124.31 Million |
| Investing Cash Flow | €-30.69 Million | €-102.81 Million | €-15.51 Million | €-2.76 Million | €7.28 Million |
| Financing Cash Flow | €-16.81 Million | €89.11 Million | €82.86 Million | €1.15 Million | €47.52 Million |
| Dividends Paid | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 |
| Stock-Based Compensation | €6.11 Million | €3.17 Million | €5.23 Million | €6.04 Million | €11.49 Million |
| Depreciation | €20.88 Million | €19.85 Million | €18.52 Million | €18.43 Million | €16.57 Million |
| Change in Cash | €-98.90 Million | €6.54 Million | €43.49 Million | €-92.42 Million | €-55.51 Million |
Cellectis Earnings History — EPS Actual vs. Analyst Estimates
Track Cellectis's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 11, 2026 | — | -0.21 | — |
| Mar 19, 2026 | -0.23 | -0.25 | +11.05% |
| Nov 07, 2025 | 0.01 | -0.14 | +103.58% |
| Aug 04, 2025 | -0.21 | -0.12 | -74.41% |
| May 12, 2025 | -0.18 | -0.23 | +21.74% |
| Mar 13, 2025 | 0.08 | -0.17 | +147.06% |
| Nov 04, 2024 | -0.23 | -0.27 | +14.81% |
| Aug 06, 2024 | -0.36 | -0.29 | -24.14% |